紫杉醇药物涂层球囊治疗动静脉内瘘功能障碍的多中心随机对照试验
该多中心随机对照试验纳入161例中国血液透析伴动静脉内瘘功能障碍患者,比较药物涂层球囊(DCB)与常规高压球囊(HPB)的疗效与安全性。DCB组6个月目标病变主要通畅率(PSVR≤2.0)显著高于对照组(65% vs 37%,P<0.001),12个月目标病变和目标通路无干预生存率亦更优,且未增加不良事件。
要点
- DCB组6个月主要通畅率65%,显著优于HPB组的37%(P<0.001)。
- DCB组12个月目标病变及通路无干预生存率均优于对照组(均P=0.04)。
- 两组主要不良事件及手术成功率无显著差异。
核心结论
- 与传统HPB相比,DCB在6个月PSVR≤2.0定义的主要通畅率及12个月目标病变和目标通路无干预生存率方面更优,且未增加不良事件。
研究设计与样本
- 多中心、前瞻性、随机、开放标签、盲终点、对照试验,纳入10个中心161例动静脉内瘘功能障碍的血液透析患者,1:1随机分组。
主要发现
- 6个月PSVR≤2.0的主要通畅率DCB组65% vs 对照组37%,率差28%(95%CI 13%-43%),P<0.001。
- 6个月目标病变无干预生存率两组差异无统计学意义(P=0.3),目标通路无干预生存率亦无统计学意义(P=0.2)。
- 12个月目标病变无干预生存率DCB组73% vs 对照组58%(P=0.04),目标通路无干预生存率73% vs 57%(P=0.04)。
- 6个月目标病变平均狭窄程度DCB组44%±16% vs 对照组49%±18%,差异无统计学意义(P=0.09)。
- 两组主要不良事件及器械、技术、临床和手术成功率均无显著差异。
关键数值与推荐
- 主要终点为目标病变主要通畅,定义为6个月时目标病变无干预生存且超声测得峰值收缩速度比(PSVR)≤2.0。
临床怎么用
- 对于中国血液透析患者动静脉内瘘功能障碍,DCB血管成形术可作为优于常规HPB的选择,以改善6个月和12个月的通畅结局。
局限性
- 样本量小;随访时间短;两组在手术操作方面存在差异,如球囊扩张时间和球囊长度不等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Previous studies have illustrated the potential superiority of drug-coated balloons (DCBs) in maintaining patency after initial angioplasty for arteriovenous fistula (AVF) dysfunction due to stenosis. Our trial evaluated the efficacy and safety of DCBs for preventing fistula restenosis in Chinese hemodialysis patients. STUDY DESIGN: Multicenter, prospective, randomized, open-label, blinded end point, controlled trial. SETTINGS & PARTICIPANTS: A total of 161 hemodialysis patients with fistula dysfunction from 10 centers in China. INTERVENTION: Participants were randomized 1:1 to treatment with initial dilation followed by DCB angioplasty or conventional high-pressure balloon (HPB) angioplasty. OUTCOMES: The primary end point was target lesion primary patency defined as the target lesion intervention-free survival in conjunction with an ultrasonography-measured peak systolic velocity ratio (PSVR) ≤2.0 at 6 months. The secondary end points included 1) device, technical, clinical, and procedural success; 2) major adverse events; 3) degree of target lesion stenosis at 6 months; and 4) clinically driven target lesion and target shunt revascularization within 12 months. RESULTS: The percentage with target lesion primary patency as defined by a PSVR ≤2.0 was higher in the DCB group than in the control group (65% vs 37%, respectively; rate difference, 28% [95% CI, 13%-43%]; P <0.001) at 6 months. The target lesion and target shunt intervention-free survival of the DCB group were not superior to those of the control group at 6 months (P = 0.3 and P = 0.2, respectively) but were superior at 12 months (target lesion intervention-free survival: 73% for DCB vs 58% for control [P = 0.04]; target shunt intervention-free survival: 73% for DCB vs 57% for control [P = 0.04]). The average degree of target lesion stenoses at 6 months was not significantly different between the 2 groups (44% ± 16% for DCB vs 49% ± 18% for control; P = 0.09). There were no significant differences in major adverse events or in device, technical, clinical, or procedural success rates between the groups. LIMITATIONS: Small sample size; short follow-up period; procedural differences between the 2 groups such as unequal inflation times and balloon lengths. CONCLUSIONS: Compared to conventional HPB angioplasty, DCB treatment achieved superior primary patency defined using PSVR measured at 6 months and superior intervention-free survival of both the target lesion and the target shunt at 12 months without evidence of greater adverse events. FUNDING: Funded by ZhuHai Cardionovum Medical Device Co., Ltd. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT02962141.
引用
- Yin Y, Shi Y, Cui T, et al. Efficacy and Safety of Paclitaxel-Coated Balloon Angioplasty for Dysfunctional Arteriovenous Fistulas: A Multicenter Randomized Controlled Trial. Am J Kidney Dis. 2021. PMID: 33418016. doi:10.1053/j.ajkd.2020.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。